BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Startups

  BridgeBio Launches GondolaBio With $300M, Transfers Programs to Joint Venture

  With the help of third-party investors, the new venture will focus on three genetic and rare diseases: tuberous sclerosis complex, erythropoietic protoporphyria and alpha-A1 antitrypsin deficiency.

  August 22, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  C-suite

  BioMarin Brings on Roche, Amgen Alums in Executive Restructuring

  As the biotech implements a more focused strategy for its Roctavian hemophilia A gene therapy, BioMarin has recruited two seasoned pharma executives to bolster its C-suite.

  August 22, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Alzheimer’s disease

  Biogen, Eisai’s Leqembi Gets UK Approval but Deemed Too Expensive by NICE

  While approved by the Medicines and Healthcare products Regulatory Agency, the Alzheimer’s drug failed to win the backing of the U.K.’s National Institute for Health and Care Excellence, which said that its benefits were “too small to justify the cost.”

  August 22, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Novartis, Versant Launch RNA Kidney Medicines—Focused Borealis

  Looking to build on the success of Chinook Therapeutics, founded by Versant in 2019 and acquired by Novartis last year, the companies on Thursday launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases.

  August 22, 2024

   · 

  2 min read

   · 

  Kate Goodwin
• 

  China

  WuXi Biologics Takes Net Profit Hit Despite Inking Record Number of New Projects

  With the potential passage of the BIOSECURE Act looming, WuXi Biologics reported a 24% drop in net profit in the first half of 2024.

  August 22, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Business

  OrthoPediatrics Corp. to Host Investor Day on September 12, 2024

  August 22, 2024

   · 

  1 min read
• Press Releases

  Expanding Access in Cancer Care: American Cancer Society and Color Health to Provide Free At-Home Colorectal Cancer Screening in Underserved Rural Communities

  August 22, 2024

   · 

  4 min read
• Press Releases

  Positive Interim Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study

  August 22, 2024

   · 

  7 min read
• Press Releases

  Registration is Now Open for Tribe Public’s Webinar Event “Now Is Not the Time to Monkey(pox) Around” Featuring GeoVax Lab’s CEO

  August 22, 2024

   · 

  3 min read
• Business

  Penumbra, Inc. to Present at the Wells Fargo Healthcare Conference

  August 22, 2024

   · 

  1 min read